Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
December 06 2023 - 4:10PM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA
medicines company committed to delivering life-changing treatments
for people battling devastating diseases, announced today that it
has commenced an underwritten public offering of $100 million in
aggregate of its ordinary shares, and, to certain investors that so
choose in lieu of ordinary shares, pre-funded warrants to purchase
ordinary shares. In connection with the offering, Wave intends to
grant the underwriters a 30-day option to purchase ordinary shares
in an amount up to an additional 15% of the total amount of
ordinary shares and pre-funded warrants sold in the public offering
on the same terms and conditions. All of the securities in the
offering will be sold by Wave Life Sciences.
J.P. Morgan and Leerink Partners are acting as joint
book-running managers for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The offering will be made only by means of a prospectus and
related prospectus supplement forming part of a shelf registration
statement that was previously filed with and declared effective by
the Securities and Exchange Commission (“SEC”). A preliminary
prospectus supplement and accompanying base prospectus relating to
and describing the terms of the offering will be filed with the SEC
and will be available on the SEC’s website located at
http://www.sec.gov, copies of which may be obtained, when
available, from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or from Leerink Partners LLC,
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, or by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@leerink.com. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA
medicines company committed to delivering life-changing treatments
for people battling devastating diseases. Wave aspires to develop
best-in-class medicines across multiple therapeutic modalities
using PRISM, the company’s proprietary discovery and drug
development platform that enables the precise design, optimization
and production of stereopure oligonucleotides. Driven by a resolute
sense of urgency, the Wave team is targeting a broad range of
genetically defined diseases so that patients and families may
realize a brighter future.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Forward-looking statements include
statements regarding the proposed public offering of ordinary
shares and pre-funded warrants to purchase ordinary shares,
including Wave’s expectations regarding the size of the proposed
public offering. These statements are subject to various risks and
uncertainties, actual results could differ materially from those
projected and Wave cautions investors not to place undue reliance
on the forward-looking statements in this press release. These
risks and uncertainties include, without limitation, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering. There
can be no assurance that Wave will be able to complete the public
offering on the anticipated terms, or at all. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, the risks and uncertainties
described in the section entitled “Risk Factors” in Wave’s
preliminary prospectus supplement related to the proposed offering
to be filed with the SEC and Wave’s most recent Annual Report on
Form 10-K filed with the SEC, as amended, and in other filings Wave
makes with the SEC from time to time. Wave undertakes no obligation
to update the information contained in this press release to
reflect subsequently occurring events or circumstances.
Investor Contact: Kate Rausch+1
617-949-4827krausch@wavelifesci.com
Media Contact: Alicia Suter +1
617-949-4817asuter@wavelifesci.com
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From Apr 2024 to May 2024
Wave Life Sciences (NASDAQ:WVE)
Historical Stock Chart
From May 2023 to May 2024